AstraZeneca Pharma India Ltd receives permission to import new drug

AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Andexanet alfa powder for solution for infusion 200 mg (Andexxa).

Through this approval, Andexanet alfa is indicated for patients treated with FXa inhibitors (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India for the specified indication, subject to the receipt of related statutory approvals, if any.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 6306.55 as compared to the previous close of Rs. 6306.30. The total number of shares traded during the day was 361 in over 95 trades.

The stock hit an intraday high of Rs. 6366.40 and intraday low of 6180.45. The net turnover during the day was Rs. 2279780.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 ImportPermission NewDrug Sale Distribution CDSCO